Praxis precision medicines to report first quarter 2024 financial results on monday, may 13, 2024

Boston, may 10, 2024 (globe newswire) -- praxis precision medicines , inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on monday, may 13, 2024, before the u.s. financial markets open.
PRAX Ratings Summary
PRAX Quant Ranking